Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers

Guido, Clara; Baldari, Clara; Maiorano, Gabriele; Mastronuzzi, Angela; Carai, Andrea; Quintarelli, Concetta; Angelis, Biagio De; Cortese, Barbara; Gigli, Giuseppe; Palamà, Ilaria Elena

doi:10.3390/diagnostics12010173

Cited by 17 publications

(19 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, targeted therapy is an attractive therapeutic approach. MEK inhibitors and BRAF V600E inhibitors have already demonstrated efficacy and are being compared to standard therapy in trials of treatment-naïve patients with LGG [30,31]. However, because these new targeted therapies frequently target genes and pathways that are critical in normal brain development, the acute and subacute long-term sequelae of molecular-targeted therapies need to be carefully monitored in children.…”

Section: Discussionmentioning

confidence: 99%

Diencephalic Syndrome Due to Optic Pathway Gliomas in Pediatric Patients: An Italian Multicenter Study

et al. 2022

View full text Add to dashboard Cite

Diencephalic syndrome (DS) is a rare pediatric condition associated with optic pathway gliomas (OPGs). Since they are slow-growing tumors, their diagnosis might be delayed, with consequences on long-term outcomes. We present a multicenter case series of nine children with DS associated with OPG, with the aim of providing relevant details about mortality and long-term sequelae. We retrospectively identified nine children (6 M) with DS (median age 14 months, range 3–26 months). Four patients had NF1-related OPGs. Children with NF1 were significantly older than sporadic cases (median (range) age in months: 21.2 (14–26) versus 10 (3–17); p = 0.015). Seven tumors were histologically confirmed as low-grade astrocytomas. All patients received upfront chemotherapy and nutritional support. Although no patient died, all of them experienced tumor progression within 5.67 years since diagnosis and were treated with several lines of chemotherapy and/or surgery. Long-term sequelae included visual, pituitary and neurological dysfunction. Despite an excellent overall survival, PFS rates are poor in OPGs with DS. These patients invariably present visual, neurological or endocrine sequelae. Therefore, functional outcomes and quality-of-life measures should be considered in prospective trials involving patients with OPGs, aiming to identify “high-risk” patients and to better individualize treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Diencephalic Syndrome Due to Optic Pathway Gliomas in Pediatric Patients: An Italian Multicenter Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Furthermore, PLGA NPs conjugated with an anti-epidermal growth factor receptor (EGFR) monoclonal antibody and loaded with curcumin achieved a reduction in the growth of EGFR-expressing GBM cells at lower concentrations than those required for free curcumin or unmodified curcumin-loaded PLGA NPs to achieve this effect [ 75 ]. Lipid-based and polymeric NPs are also being explored for the delivery of chemotherapeutic agents in paediatric cancers (for review see Guido et al, 2022 [ 76 ]).…”

Section: Nanotechnology For Bbb Crossingmentioning

confidence: 99%

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood–brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

show abstract

“…Imaging contrast parameters-based nanotechnology are being updated every day and are specifically presented an ability for detection the tumors in vivo compared with conventional scanning devices [14][15][16] . Furthermore, the platforms of nanoscale imaging have novel patterns with a lower health risk and a higher penetration 17 .…”

Section: Cancer Bioimaging Using Dual Mode Luminescence Of Graphene/f...mentioning

confidence: 99%

Cancer bioimaging using dual mode luminescence of graphene/FA-ZnO nanocomposite based on novel green technique

Wanas

El-Kaream

Ebrahim

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Graphene based nanomaterials are explored in the field of cancer bioimaging and biomedical science and engineering. The luminescent nanostructures with a low toxicity and high photostability can be used as probes in bioimaging applications. This work is aimed to prepare graphene/folic acid-zinc oxide (GN/FA-ZnO) nanocomposite with dual-mode emissions (down-conversion and up-conversion) to be used in cancer bioimaging. The dual mode emissions offer long luminescence lifetime, multicolor emissions detected by the naked eyes after excitation and narrow band absorption and emission spectra. ZnO nanospheres and nanorods structures were prepared using co-precipitation technique and were conjugated with FA to separate the bulk graphite layers electrostatically into GN. The optical, morphological, surface charge and structural properties of the prepared nanostructures were investigated and discussed using different characterization techniques such as UV–visible spectroscopy, photoluminescence (PL) spectroscopy, scanning electron microscope (SEM), high resolution transmission electron microscope (HRTEM), Zeta potential, Raman spectroscopy, X-ray photoelectron spectroscopy (XPS), X-ray powder diffraction (XRD), and Fourier transform infrared (FTIR). GN/FA-ZnO nanocomposites were injected into Swiss albino mice implanted with Ehrlich Tumor and the bioimaging was investigated using photon imager and digital camera. The results showed clear fluorescence and confirmed that the green design of GN/FA-ZnO nanocomposite with targeting behavior was capable of selective bioimaging of the tumor. This study presented a novel dual mode emission nanocomposite for tumor targeting and is a promising strategy for the fabrication of a new design of spectral encoding.

show abstract

Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers

Cited by 17 publications

References 114 publications

Diencephalic Syndrome Due to Optic Pathway Gliomas in Pediatric Patients: An Italian Multicenter Study

Diencephalic Syndrome Due to Optic Pathway Gliomas in Pediatric Patients: An Italian Multicenter Study

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Cancer bioimaging using dual mode luminescence of graphene/FA-ZnO nanocomposite based on novel green technique

Contact Info

Product

Resources

About